American Society of Hematology

2023 Call for Abstracts

December 9-12, 2023 | San Diego, California

Information for Authors
The 65th ASH Annual Meeting and Exposition will be held Saturday, December 9, through Tuesday, December 12, 2023, in San Diego, California. The meeting will be in person, with a virtual attendance option, however, presenting authors are required to be onsite in San Diego. The goal of the ASH annual meeting is to present the best new basic, translational, clinical, and epidemiological research in all areas of hematology. The meeting content will also be accessible to virtual meeting attendees via the virtual meeting platform.

All abstract submissions must be made electronically through ASH’s online abstract submission system. The site opens on Thursday, June 1, 2023, and the abstract submission deadline is Tuesday, August 1, 2023, 11:59 p.m. (Pacific time.).
# Table of CONTENTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Important Dates</td>
<td>4</td>
</tr>
<tr>
<td>Eligibility</td>
<td>4</td>
</tr>
<tr>
<td>Responsibilities of the Presenting Author</td>
<td>5</td>
</tr>
<tr>
<td>Copyright and Ownership</td>
<td>8</td>
</tr>
<tr>
<td>Abstract Submission Guidelines</td>
<td>9</td>
</tr>
<tr>
<td>How to Submit an Abstract</td>
<td>12</td>
</tr>
<tr>
<td>Contact Information</td>
<td>15</td>
</tr>
</tbody>
</table>
Eligibility

The following criteria must be met for abstract submission:

- At least one of the authors must be a current ASH member with up-to-date payment of membership dues.
- If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of each abstract that they sponsor.
- The content of the abstract must fit into one of the ASH 2023 Abstract Review Categories.
- In contrast to past years, oral abstracts and poster presentations will no longer be contained in the ACCME-accredited portion of the Annual Meeting. Therefore, presenting authors are no longer subject to ACCME restrictions, and can be employees of publicly-traded or privately-held healthcare companies or owners of privately-held entities. All relevant conflicts of interest must be disclosed, and data presented fairly and transparently.
- Updated analyses of work previously presented at ASH or other meetings of more than 1,000 participants will be considered only if the abstract is a significant extension of previously presented work. The author must provide an explanation documenting the significant new information.
- Data are to be presented at an ASH Friday Satellite Symposium, scheduled for December 8, 2023.

Abstract preprint criteria:

- Abstracts describing work posted to a preprint server before submission to ASH will be considered but preprint posting must be disclosed, and a link to the preprint provided. Authors must retain copyright of the abstract so that it may be transferred to the American Society of Hematology if the abstract is accepted, per ASH’s copyright policy.
• Once the abstract has been submitted to ASH, no further changes can be made to the preprint or the abstract, and the preprint may not be updated if the abstract is accepted for presentation at ASH.

• Upon abstract acceptance for presentation at the Annual Meeting, the content and conclusion of the abstract are embargoed from publication.

Responsibilities of the Presenting Author

• The first author of the abstract serves as the presenting author and as the primary contact for all correspondence about the abstract unless otherwise specified under the “Contact Information” section of the online abstract submission system.

• The presenting author must be one of the co-authors of the abstract.

• The presenting author is responsible for:
  - Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to obtain approval from all authors will result in rejection of the abstract;
  - Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH;
  - Obtaining copyright transfer consent from all co-authors;
  - Forwarding all correspondence to all co-authors, including ASH policies and guidelines on the disclosure of financial relationships.

• Unless announced otherwise by ASH, the presenting authors of abstracts accepted for oral or poster presentation must attend the 2023 Annual Meeting in person in San Diego. If the original designated presenting author cannot attend, a co-author may be designated as an alternative presenter.

Authors’ Consent and Waiver of Claims

• Each abstract author agrees and certifies that they:
  - Have read all the rules and agree to be bound by them;
  - Are responsible for the submission of the abstract in accordance with ASH’s guidelines; and
  - Waive any and all claims against ASH and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
Abstract Policies

Abstract Content

• An abstract must include primary scientific, clinical, meta-analytic, health outcomes, or epidemiologic data. The only exceptions are Trials in Progress abstracts (see Trials in Progress Section for information on criteria for a TiP abstract).

• All studies reported in submitted abstracts involving human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.

• Data from the long-term follow-up of previously presented or published clinical trials may be submitted only if they include significant new information. Submitter must use the Updated Analyses section of the abstract form to explain the extent and the significance of new data. The reviewers will have this information available during their evaluation.

• Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and if it is statistically valid. If the abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of the study. The reviewers will have this information available during their evaluation.

Editorial Policy Regarding Machine Learning (ML) & Artificial Intelligence (AI) Tools

• ML/AI tools are not eligible for authorship, and may not be listed as an author.

• Research that used ML/AI tools for data acquisition or analysis is eligible for submission.

• Submissions may include graphic outputs of ML/AI tools, as long as the role of ML/AI in creating the graphics is specified in the legend.

• Text generated by AI may not be included in the abstract.

Trials in Progress

Abstracts of Trials in Progress (TiP), i.e., descriptions of trials that have not reached the primary endpoint and do not include any clinical data, are eligible for submission to the ASH Annual Meeting. TiP abstracts are expected to provide investigators with opportunities to discuss planned and ongoing clinical trials with other clinical and industry investigators, hematologists interested in referring patients, translational researchers, statisticians, and regulators. The TiP poster platform will help increase the visibility
Trials in Progress submissions will only be considered for poster presentations and will be designated as TiPs in the poster hall. TiPs will be selected for poster presentation by dedicated review panels only considering the pool of submitted TiP abstracts. Any abstract submitted as a TiP that contains clinical endpoint or other clinical data will be immediately withdrawn from consideration. Thus, abstract authors should submit abstracts containing any interim clinical trial results as regular abstracts, NOT as TiPs.

In addition to the regular eligibility criteria listed above, TiP abstracts must fulfill the following criteria:

• The trial described must fit into one of the ASH 2023 Abstract Review Categories.
• The clinical trial registration number (with ClinicalTrials.gov or another accepted clinical trials registry) must be provided in the abstract.
• Clinical studies submitted as TiP abstracts must be in the study design phase or if active or ongoing should not have reached the clinical endpoints for analysis. All phases of clinical research interventional studies (phase I to III, supportive care, nonpharmacologic interventions) may be considered as a TiP submission.
• Abstracts containing ANY clinical endpoint or other clinical data submitted as a TiP will be deemed ineligible and completely withdrawn from consideration for presentation at the ASH Annual Meeting.

A TiP abstract submission should include:

• Background and Significance: TiP abstracts should contain the scientific rationale for the trial to be presented, for instance, information on preclinical studies as well as previously published clinical data that informed and helped guide the development of the current study.

• Study Design and Methods: The study design should highlight any innovative features of trial design, analytic methodologies, or study drugs and/or treatment modalities. It must include:
  • A clinical trial registration number as detailed above;
  • A description of the study population;
  • General location of participating centers (single center, or multicenter, whether a single country, region or worldwide);
  • Major inclusion and exclusion criteria;
  • Statistical methods;
  • Biomarker selection or companion diagnostics (if appropriate); and
  • Study treatment and relevant primary and other endpoints.

Abstracts submitted to ASH are embargoed from the time of submission. This means that the data in the abstract cannot be published in a journal once the abstract has been submitted for the ASH Annual meeting until the meeting has concluded. (The exception for abstracts submitted to other ASH meetings in the Eligibility section. Read the Annual Meeting “Embargo Policy” webpage for more details.)
Conflict of Interest Disclosure
ASH is committed to ensuring the integrity of its scientific, educational, and research programs. The ASH Conflict-of-Interest Policy requires disclosure of any financial or other interest in the biomedical industry that might be construed as resulting in an actual, potential, or apparent conflict, regardless of the relationship's pertinence to the abstract, or abstracts if the author is associated with more than one abstract submitted to ASH.

By completing this section of the online abstract submission, the submitter agrees that they have read the ASH Conflict-of-Interest Policy and understand and support its intent.

Copyright and Ownership

Abstract Copyright Transfer
Authors assign copyright of the abstract to ASH upon submission, unless one of the authors is a U.S. Federal employee (in such case, ASH does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.

Ownership of Abstract-Related Materials
Materials presented at the ASH Annual Meeting or requested for submission by ASH in conjunction with the annual meeting, other than abstracts, including but not limited to posters, on-screen presentations (e.g. PowerPoint slides, pre-recorded presentations) and hand-outs are the intellectual property of individual presenters or entities other than ASH. See the licensing policy below for more information.

Licensing Agreement for Abstract-Related Materials
By presenting at the ASH Annual Meeting, the presenter: (a) certifies that he or she holds the copyright to the presentation materials or has obtained appropriate authorization from the copyright holder to use, and to permit ASH to use, the presentation materials; and (b) grants ASH “the exclusive right to record, broadcast, create plain language summaries, and otherwise use in all media, the presentation, and all documents (including slides) displayed or distributed in connection with the presentation (collectively, the “Work”),” as well as the right to use the presenter’s “name, likeness, voice, and biographical information in connection with” the Work.

Reuse of ASH Annual Meeting Materials
The ASH Annual Meeting & Exposition is convened to present the best new basic, translational, clinical, and epidemiological research in all areas of hematology. Material presented at the Annual Meeting is subject to copyright or other reuse restrictions. Information about these restrictions, and guidelines on ASH’s reuse policies are detailed below.

Reuse of Abstracts
Abstracts submitted to the 65th ASH Annual Meeting and Exposition are copyrighted by the American Society of Hematology and published in a supplemental issue of the Blood Journal. Other than the rights specifically granted to abstract authors (see below), any reproduction, distribution, or transmission of the abstracts in whole or in part, by electronic, mechanical, or other means, or other intended use, is prohibited without the expressed written consent of ASH.

Rights Granted to Abstract Authors
ASH grants each abstract author the following royalty-free rights, subject only to the acknowledgment of ASH’s copyright and to the author’s compliance with the ASH Annual Meeting embargo policy:

- Reprinting the abstract in print collections of the author’s own writing;
- Reusing the abstract’s figures and tables created by the author in future works;
- Reproducing the abstract for use in courses the author is teaching. If the author is employed by an academic institution, that institution may also reproduce the article for course teaching;
- Distributing photocopies of the abstract to colleagues for non-commercial purposes;
- Posting a copy of the abstract on the author’s personal website, departmental website, and/or the university intranet (a hyperlink to the abstract on the Blood website must be included);
• Presenting the abstract orally in its entirety for non-commercial purposes; and
• Using the abstract in theses and/or dissertations.

Authors reusing their own material in the above ways must include appropriate attribution and do not need to contact Blood for permission but must comply with the Annual Meeting embargo policy. For all other uses, the author must request permission by visiting the Copyright Clearance Center.

Any reproduction of the abstract in whole, or in part, must be accompanied by an acknowledgement of ASH’s copyright in the following form: © American Society of Hematology (Year). Reused with permission.

Non-Authors or other entities must obtain written permission to republish any parts of works owned by ASH prior to usage (see the “permission to re-use” section below).

Reuse of Abstract-Related Presentation Materials
Pursuant to the rights granted exclusively to ASH, written permission from ASH is required to use the presentation and any related materials contained in, or distributed in connection with, that presentation in any media.

Permission to Reuse
ASH expects that all (commercial and individual) Annual Meeting participants will respect its intellectual property rights and use its material solely as permitted by Sections 107 and 108 of the U.S. Copyright Law (Fair Use).

For permission to use an ASH Annual Meeting abstract or abstract-related material beyond what is permitted by Sections 107 or 108 of the U.S. Copyright Law, please visit the Copyright Clearance Center.

Abstract Submission Guidelines

Submission
• No revisions to the abstract content can be made after the abstract submission deadline (August 1). This includes changes to the spelling of authors’ names and the order of co-authors.

Please proofread your abstract to ensure that it does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted.

• Abstracts should be written in clear and concise English so that reviewers can focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling before submission.

• During online submission, you must indicate whether you prefer to have your abstract withdrawn if it is accepted as “publication only”. Abstracts may not be withdrawn after September 15, 2023.

• There is an $85 nonrefundable handling fee for each abstract submission. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the Annual Meeting; therefore, all authors planning to attend the ASH Annual Meeting must register for the meeting.

• During submission, ASH staff are authorized to communicate with the corresponding author. After acceptance, ASH staff will only communicate with the presenting author regarding any abstract-related matters, including requests for withdrawal which must be submitted in writing. Any queries or requests from co-authors or non-authors, including pharmaceutical companies or medical communications companies, must go through the presenting author.

Presentation Format
• During submission, the authors may elect to have their abstract considered for a “poster-only” presentation. By making this selection,
your abstract will not be considered for oral presentation, regardless of the score. Choose this option if you are unwilling or unable to give an oral presentation in English. This choice must be made at the time of submission and cannot be changed after the Review Committee has reached its decision.

- During submission the author must indicate if they want to have the abstract withdrawn if it is accepted as “publication-only”. Depending on the number of submissions and the space constraints at the venue, ASH may not be able to accommodate all qualified submissions for an oral or poster presentation. In such a case, the submission may be accepted and designated as “publication-only.” Publication-only submissions will be published in the online-only abstract supplement of Blood (which is part of the permanent Blood archive) but will NOT be scheduled for presentation at the Annual Meeting, nor featured in the web program, the Meeting App, or the Virtual Meeting Platform.

**Presentation**

The presentation at the Annual Meeting must reflect the content of the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation must match the submitted abstract, although updated results may be included.

Abstracts cannot be changed after the submission deadline (August 1) and may not be withdrawn after September 15, 2023.

**Presentation Materials and Guidelines**

ASH requires that ALL poster presenters submit a pre-recorded MP4 and a PDF version of their poster presentation (oral presenters are not required to pre-submit a recorded presentation). The MP4 file will be included in the virtual meeting platform and the PDF file will be printed and displayed onsite in the poster hall and included in our e-poster library. The deadline for submission of pre-recorded presentations, PowerPoint slides, and posters is November 14, 2023.

- Pre-recorded presentations for poster presentations must be submitted by November 14th
- Poster presentations will consist of 3-5 minute recordings accompanying a slide deck on the virtual platform.
- Failure to submit a presentation by November 14th will result in the removal of presenting privileges and be noted as “Presentation Not Available” in meeting materials.

**Abstract Review and Selection**

- After the submission deadline, all completed and eligible abstracts will be made available to the ASH abstract reviewers for anonymized review and scoring, and final decisions will be made by the Review Committee in late September 2023.
- Abstracts will be evaluated and scored solely on their scientific merits. Trials in Progress abstracts will be flagged and reviewers will be provided additional guidance for reviewing them (based on the novelty of the methodology, quality of the study design, and interest to the hematology community).
- The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
- Abstracts will be peer-reviewed according to the subject categories. Authors must indicate the appropriate review category (one only) during online submission. Please use the list of updated abstract review categories when selecting the abstract classification. Read through all the categories and select the category most closely associated with your abstract. Authors will not be able to reclassify their abstracts after the abstract submission site closes. The ASH Secretary may move abstracts between categories as deemed appropriate, however, abstracts submitted to an inappropriate category may be scored in that category and are often ranked poorly.

- The Plenary Session features six of the highest-scored abstracts submitted to the Annual Meeting, chosen by the ASH Program Committee for their quality, significance, and general interest. These abstracts are introduced in the Plenary Session by an ASH member selected to place the abstract in context for a general hematology audience, followed by the author’s presentation and a brief discussion.
- Oral (simultaneous) Sessions consist of 10-minute oral abstract presentations followed by a 5-minute discussion.
- Poster Sessions allow in-person viewing of a poster illustration of the abstract. Poster presenters are required to record a 3-5 minute PowerPoint presentation of their poster, as well as provide a graphic image for both in-person and virtual attendees. In-person presenters are expected to be at their posters to answer questions during their assigned poster presentation time. The author’s attendance during the poster presentation will be monitored.

Acceptance/Rejection Notification

- Notification regarding acceptance or rejection of abstracts will be sent via e-mail to the presenting authors in early October; consequently, providing an accurate e-mail address at submission is critical. If your abstract is accepted, the e-mail will specify whether it is accepted as a plenary, oral, or poster presentation or whether it will be published online only, without a presentation. If you have not received an e-mail notification by October 5, 2023, contact ASHAbstracts@hematology.org.
- To ensure that you can receive e-mail correspondence from ASH, please make sure that your e-mail software can receive mail from the confex.com and hematology.org domains. You should add ash@confex.com and ASHAbstracts@hematology.org to your Safe Senders list and/or address book. If after completing your submission you don't receive a confirmation e-mail from the abstract system, you must contact your system administrator and make sure that both the confex.com and hematology.org domains are added to your permitted e-mail address list. The decision of the ASH Program Committee regarding the acceptance and presentation of abstracts is final.

Abstract Withdrawal

- Once an abstract has been accepted, a written request to withdraw must be submitted no later than September 15, 2023, to ASHAbstracts@hematology.org by the presenting author to withdraw the abstract for any reason. Abstracts will not be withdrawn after this deadline. No person other than the presenting author may contact ASH to request a withdrawal. The submitting author must ensure that all authors are aware of this policy and agree to honor it.
- ASH reserves the right to withdraw abstracts that violate the Society's policies and guidelines, such as those that have been previously published or presented, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
- If you indicated at submission that you wish to withdraw your abstract if it is not accepted for presentation, it will be automatically withdrawn and you will be notified; you do not need to request a withdrawal.

Abstract Cancellation

- If after the September 15 withdrawal deadline, the presenting author of a poster is unable to attend the meeting in person and a co-author cannot be identified to replace the presenter, the author should submit a request to ASHAbstracts@hematology.org to cancel the presentation. A poster cancellation means that a “canceled” sign will be hung on your assigned poster board on the presentation date. The abstract will remain published in the virtual program, mobile app, and Blood supplement.

Publication in the Abstracts Supplement of Blood, a Journal of the American Society of Hematology

- All abstracts accepted for presentation (plenary, oral, or poster) at the ASH Annual Meeting are published in a special online-only supplement of Blood, ASH's official journal, on the Blood Abstracts website.
- Abstracts not selected for presentation will also be published online only, on the Blood Abstracts website. If an author does not want an abstract published if not accepted for presentation, the author must indicate that during submission. Publication permission cannot be withdrawn after abstract notification.
- ASH reserves the right not to publish abstracts that do not fit into any of the review categories, abstracts that inappropriately promote commercial interests in the biomedical industry, abstracts that are judged unethical, poorly written, or scientifically unsound, or abstracts considered inappropriate for publication for other reasons as determined by the ASH Program Committee.

Late-Breaking Abstracts

Recognizing that the results of timely top-quality research may not always be available by the general abstract submission deadline, the ASH Program
Committee offers an option for late-breaking abstracts.

- The late-breaking abstract submission site will open October 17 and close October 26, 2023.
- During submission, authors of late-breaking abstracts will need to explain why their abstract was not ready by the regular deadline (August 1) and why it deserves to be considered late-breaking. This information will be available to reviewers.
- On average only six abstracts will be accepted and presented in the Late-Breaking abstracts session on Tuesday, December 12. Selection for presentation is extremely competitive, with the quality and general significance of the presented Late-Breaking abstracts equivalent to Plenary Session or the top oral session abstracts.
- There is a $125 nonrefundable handling fee for submitting a late-breaking abstract. Payment must be made by credit card: Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted.
- Late-breaking abstracts will undergo peer-review evaluation.
- Work already posted to a preprint server will not be considered for the Late-Breaking Abstracts session.
- Accepted abstracts will be published online only on the Blood Abstracts website. Late-breaking abstracts not accepted for presentation will not be published in any form.

---

**How to Submit an Abstract**

**Important Submission Information**

The abstract submission site is open June 1–August 1, 2023.

All abstracts must be submitted by August 1, 2023, at 11:59 p.m. Pacific Time.

All submissions deemed to be incomplete by this deadline will be rejected.

**Additional Submission Details**

- Abstracts must be submitted online through the official online abstract submission system. Abstracts sent via e-mail to ASH will not be accepted.
- There is an $85 non-refundable handling fee for each abstract submission. Payment must be made by credit card: Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the ASH Annual Meeting; therefore, all authors planning to attend the Annual Meeting must register by visiting the ASH Annual Meeting webpage.
- The electronic submission system is compatible with PC Windows and Apple computers and with most browsers, including Google Chrome, Mozilla Firefox, Internet Explorer, Safari, and Netscape. The online abstract submission system will provide links for free browser downloads.
- If this is your first time submitting an abstract for the ASH Annual Meeting, please be sure to check the box indicating so during submission.
- Once you have submitted the title of the abstract, a draft of your abstract will be saved and you will be able to return to the site to edit and update the submission at any time until August 1, 2023, at 11:59 p.m. PDT. Revisions will not be accepted after the submission deadline. You will receive an e-mail with a link to your submission.
- Abstracts cannot be submitted and will not be reviewed without proper payment and completion of the “Submission Information” and “Disclosure” sections of the online abstract submission program.
- Any technical questions regarding the navigation of the submission site should be directed to ash@confex.com. Authors should not leave submission of the abstract for
the final day or hours so that ASH staff and Confex can have time to assist you with any technical problems that may arise during the submission process.

Preparing an Abstract

Contact Information

- The corresponding author must provide their name, degree, institutional affiliation, address, phone number, and e-mail address. All correspondence from ASH will be sent to the corresponding author during the submission period.

- If none of the abstract authors is an ASH member, the program will ask you to provide the name of the ASH member sponsoring the abstract.

Co-Authors

- The names of all co-authors and their institutional affiliations must be provided. Please proofread the co-authors’ names carefully.

- Changes will not be made to the spelling of authors’ names, or the order of co-authors, after the submission deadline; please proof your co-authors’ names and order carefully.

Abstract Title

- The abstract title should be brief and clearly indicate the nature of the abstract.

- The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase “to” when used as an infinitive.

- Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.

- Do not put a period at the end of the title.

- For example: Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies

Use of Product Names

- Non-proprietary (generic/scientific) names should be used and should be lowercase.

- If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in

the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ASH reserves the right to replace proprietary names with generic names to adhere to this policy.

Abbreviations

- Use standard abbreviations. Include abbreviations in parentheses immediately after the first mention of a term or phrase.

Abstract Body, Tables, and Figures

- Abstracts submitted for the ASH Annual Meeting are published in a special online-only November 2023 supplement of Blood. Abstracts will be typeset from the text submitted by the author without copyediting changes. IT IS THE RESPONSIBILITY OF THE AUTHOR TO PROOFREAD THE ABSTRACT AND AUTHOR LIST CAREFULLY.

- The entire body of the abstract, excluding tables and spaces, must not exceed 3,800 characters. The title, authors’ names, affiliations, figures, and tables are not included in the character count.

- The body of the abstract should be pasted into the submission form. Tables and figures may be uploaded via photo file type.

- The abstract may be structured (i.e., divided into sections: Introduction, Methods, Results, and Conclusions) or unstructured.

- Do not use bold type or underline formatting. Italic type is acceptable.

- Text may be in multiple paragraphs.

- Special Greek and mathematical symbols are available in a character map within the submission system. Pay careful attention to superscripts, type case font sizes, and special characters when copying/pasting abstract text.

- Use numerals to indicate numbers, except when beginning sentences.

- Abstracts may include no more than two panels of additional content such as figures or tables. A “panel” would be defined as a table or a single graphical representation of data, equivalent to a figure panel in a paper.

- All tables and figures must be uploaded as a single image file. Do not paste a table directly into the text of the abstract, rather, include it as an image in the appropriate place and use the upload method to submit your abstract. To convert a table to an image, we recommend taking a screenshot of the table. If using a PC, use the Snipping Tool or the Print Screen
button. If using a Mac, press Command-Shift-4. An image can also be created by exporting your table in MS Word to PDF format and then converting the file to an image.

- Any references should be noted as citations within the text and not as footnotes at the end of the abstract.

**Selection of Abstract Review Category**

- Please refer to the list of this year’s categories to assist you in selecting the correct abstract category. Categories are frequently redefined; please read through each category before making your selection.
- Abstracts will be reviewed in the category you select.

**Abstract Awards**

Each year, ASH offers the following merit-based awards to support select trainees with high-achieving annual meeting abstracts who are chosen to present their work at the ASH annual meeting. Trainees include those who fall within one of the following categories: undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow (MD or PhD). The benefits vary by award.

**ABSTRACT ACHIEVEMENT AWARDS**

Historically, these $500 merit-based awards (formerly Travel Awards) are provided to trainees with high-scoring annual meeting abstracts of which they are the first or senior author and presenter in order to defray travel expenses to the annual meeting.

**OUTSTANDING ABSTRACT ACHIEVEMENT AWARDS**

These $2,000 awards are provided to trainees with the highest scoring abstract (in each trainee category) of which they are the first author and presenter. Awardees also receive annual meeting travel reimbursement (coach airfare and two nights’ hotel accommodations) in addition to the award.

Travel reimbursement is contingent on presenting in person at the annual meeting and is not applicable for virtual presentations.

The following individual awards are also part of the ASH Abstract Achievement Award program:

- Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis
- ASH-Frank Toohey Abstract Achievement Award for Myelodysplastic Syndromes
- Joanne Levy, MD, Memorial Award for Outstanding Achievement
- Minority Graduate Student Abstract Achievement Award (MGSAAA)
- ASH Giuseppe Bigi Memorial Award
• ASH-IPIG Abstract Achievement Award for Paroxysmal Nocturnal Hemoglobinuria (PNH)
• National Partner Society Abstract Achievement Awards

How to Apply for Abstract Awards

To be considered, individuals must meet specific eligibility criteria for the desired award and fall within (and select their trainee level from) one of the following trainee categories: undergraduate student, medical student, graduate student, resident physician, or postdoctoral fellow (MD or PhD).

Applicants must check the appropriate box in the area marked “Abstract Achievement/ Outstanding Abstract Achievement Award Applicants” during the online abstract submission process. Applicants must also include with their abstract submission a letter from their Training Program Director confirming status as a trainee.

For the individual awards that are also part of the Abstract Achievement Award program, please visit https://www.hematology.org/awards/achievement-awards to view additional eligibility requirements and application instructions.

Electronic Signature

Completion of all required disclosure information in the online abstract submission system serves as an agreement between ASH and the submitting author and is accepted in place of a faxed signature. It certifies the submitter's understanding of submission rules and affirms that:

1. All authors approve abstract submission and, presentation and publication of their work;
2. The author(s) transfer(s) all copyright ownership of the abstract to the American Society of Hematology (except when one or more authors are U.S. Government employees);
3. All authors have read the ASH Conflict-of-Interest Policy and have abided by that policy;
4. The author(s) agree(s) to materially confine the presentation to information presented in the abstract if the abstract is accepted for presentation. If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session;
5. The presenting author will be available to present the abstract in person if selected for the program. The author(s) will immediately notify ASH if the presenting author must be changed;
6. The data in the abstract have not been accepted for publication elsewhere before the ASH submission deadline, nor will they be materially presented at a meeting of 1,000 or more participants before the ASH Annual Meeting (note the exception for abstracts submitted to other ASH meetings in the Eligibility section). In addition, the data are not to be presented at an ASH Friday Satellite Symposium. If the data have been made available on a preprint server, all ASH policies summarized above regarding preprints have been and will be followed.
7. The author(s) are aware that the withdrawal deadline for ASH Annual Meeting abstracts is September 15, 2023, and understand that abstracts cannot be withdrawn after September 15.

Sample Abstract

A sample abstract is available for reference at https://ash.confex.com/ash/f/sampleabstract

Contact Information

All correspondence and questions regarding abstract submission policies or notifications should be sent to ASHAbstracts@hematology.org.

Any technical questions about the use of the submission site should be directed to ash@confex.com.

ASH Annual Meeting Registration and Housing

Submitting an abstract does not register you for the ASH Annual Meeting. To register, please visit hematology.org/meetings/annual-meeting.